Logo

Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain

1, 2, 3

  1. Department of Internal Medicine, Division of Rheumatology, Rush University Medical Center, Chicago IL, USA.
  2. Department of Internal Medicine, Division of Rheumatology, Rush University Medical Center, Chicago IL, USA.
  3. Department of Internal Medicine, Division of Rheumatology, Rush University Medical Center, Chicago IL, USA. joel_block@rush.edu

CER10822 Submission on line
2017 Vol.35, N°5 ,Suppl.107 - PI 0085, PF 0087
Pain in osteoarthritis

Free to view (click on article PDF icon to read the article)

Rheumatology Article

 

Abstract

Blockade of nerve growth factor (NGF) with antibodies is a promising strategy for treatment of chronic pain associated with osteoarthritis (OA). This narrative review describes the current status of NGF-blockade for the treatment of OA pain. We summarise briefly current evidence for the efficacy and risks of anti-NGF blockade. Two anti-NGF antibodies, tanuzemab and fasinumab, are in active development, with tanuzemab close to completing Phase 3 trials in preparation for an application for approval for clinical use.

PMID: 28967370 [PubMed]

Received: 16/09/2017 - Accepted : 16/09/2017 - In Press: 28/09/2017 - Published: 29/09/2017